Gynecologic Oncology Research Group
Click on the blue text below for more
information
Principal Investigator
Collaborating Faculty
|
Bethany
Hannafon, PhD, Assistant Professor of Research Exosome and miRNA Breast Cancer Biomarkers |
|
|||
|
Vishal Chandra, PhD, Assistant Professor or Research Endometrial Cancer Prevention and Treatment |
|
|||
|
Satish Ramraj, PhD, Postdoctoral Fellow Prevention of Fallopian Tube Carcinogenesis
to Ovarian Cancer |
|
Postdoctoral Fellows
|
Rajani Rai, PhD Prevention of Tobacco Carcinogenesis |
|
|
Sugantha Priya Elayapillai, PhD Repurposing Mebendazole for Ovarian Cancer |
|
Students
|
Amy Bosley, BA, Pathology Department Combination Drug Therapy for Cervical Cancer |
|
|
Zitha Isingizwe, BS, Pharmaceutical Sciences Department How to prevent platelet promotion of ovarian
cancer |
|
Current Research
Projects:
How does ovarian cancer develop from
the fallopian tube and how can it be prevented?
Recent
Publications:
|
Benbrook, D. M.,
Janakiram, N. B., Chandra, V.*, Pathurib,
G., Madk, V., Stratton, N. C., Masamha,
C. P, Farnsworth, C. N., Garcia-Contreras, L., Hatipoglu, M. K., Lightfoot,
S., Rao, C. V. (2018). Development of
a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational
New Drugs, 36(4), 561-570. PMID: 29273857. DOI: 10.1007/s10637-017-0550-0 |
|
Ramraj, S. K., Smith, K. M., Janakiram, N. B., Toal, C., Raman, A., Benbrook, D. M. (2018). Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue & cell, 52, 57-64. PMID: 29857829. DOI: 10.1016/j.tice.2018.04.001 |
Current
Funding:
Benbrook, D. M. (Principal Investigator), 40% Effort, Rao, C. (Co-Investigator), Janakiram, N. (Co-Investigator), Garcia-Contreras, L. (Co-Investigator), Woo, S. (Co-Investigator), Zuna, R. (Co-Investigator), Crouse, E. (Co-Investigator),
Ovarian
Cancer Chemoprevention
Peer-reviewed Nationally-funded
Research Grant, Sponsored by National Cancer Institute, Federal Grant/Contract Number: R01
CA196200/C31042101
Current Funding (Total Cost per Year): $503,992
Total Direct Costs Per
Year: $340,535
July 1, 2015 - June 30, 2020
Benbrook, D. M. (Principal Investigator)
"cGMP NSC 721689 Production for IRB-approved and NCI-funded Clinical Trials,"
Sponsored by NCI PREVENT, Federal
Grant/Contract Number: 721689
February 10, 2015 - Present
How do HPV and tobacco cause cervical cancer and how can it be
prevented and treated?
Current Funding:
Benbrook, D. M.
(Principal Investigator), 30% Effort, Rao, C. (Co-Principal Investigator),
Zuna, R. (Co-Investigator), Garcia-Contreras, L. (Co-Principal Investigator),
Woo, S. (Co-Principal Investigator), Zhao, D. (Co-Investigator), Frumovitz, M. (Co-Principal Investigator), Coleman, R.
(Co-Principal Investigator),
Targeting
HPV Consequences in a Cervical Cancer Clinical Trial Peer-reviewed,
federally-funded research grant, Sponsored by NIH/NCI, Federal Grant/Contract
Number: R01 CA200126/C3111201
Current Funding (Total Cost per Year): $595,072
Total Direct Costs: $425,303.00
June 1, 2016 - May 31,
2022
How do estrogen and obesity cause endometrial cancer and how can
it be prevented and treated?
Recent
Publications:
Chandra,
V., Kim, J. J., Benbrook, D. M., Dwivedi, A., Rai, R.#, Gyeongbuk, G. (2016). Therapeutic
options for management of endometrial hyperplasia: An update. J Gynecol Oncol, 27(1). PMID:
26463434. DOI: 10.3802/jgo.2016.27.e8
Current Funding:
Benbrook, D. M. (Project Director), Chandra, V. (Co-Project Director), Rai, R. (Co-Project Director), Rao, C. (Principal Investigator), Chemoprevention of Endometrial Hyperplasia and Its Transition to Endometrial Cancer with NSC 721689
Sponsored by NCI PREVENT Program,
Federal Direct Total Costs $713,988
June 16, 2017 - June 14, 2019
Can glycoprotein expression in tumor biopsies predict cervical
cancer lymph node metastases?
Clinical Trial:
Benbrook, D. M. (Study
Co-Chair), Gold, M. A. (Study Chair), Cummings, R. (Study Co-Chair), Rodgers,
W. (Study Co-Chair), Comparison of
Glycoprotein Expression and T-Synthase Function in Primary versus Metastatic
Tumors
Sponsored by Gynecologic Oncology
Group, Foundation Grant/Contract Number: GOG - 0221
April 13, 2007 - August 24, 2017